Literature DB >> 7932887

Massive steroids do not reduce the zone of injury after penetrating spinal cord injury.

M R Prendergast1, J M Saxe, A M Ledgerwood, C E Lucas, W F Lucas.   

Abstract

The National Acute Spinal Cord Injury Study II concluded in 1990 that high-dose methylprednisolone (MP) improved neurologic recovery after acute spinal cord injury (ASCI). We tested this conclusion by analysis of 54 patients with ASCI; 25 patients were treated without MP before 1990 whereas 29 patients were treated with MP after 1990. Neurologic deficit was assessed regularly, in most cases daily. Motor and sensory scores on admission, and best results at one-half week (days 2 to 4), 1 week (days 6 to 10), 2 weeks (days 11 to 21), 1 month, and 2 months were noted for both groups. Motor assessment was recorded in 22 muscle segments on a scale of 0 (complete deficit) to 5 (normal); the range, thus, was 0 to 110. The 23 patients with closed injuries demonstrated no difference in improvement with or without MP. In contrast, MP was associated with impaired improvement in the patients with penetrating wounds; the 15 patients with no MP therapy had an admission motor score of 49, which increased by 6.9 at one-half week, whereas the 16 patients treated with MP had an admission motor score of 48, which decreased by 0.3 at one-half week (p = 0.03). The neural status seen by day 4 persisted throughout the next 2 months. Changes in sensation paralleled the changes in motor function. We conclude that MP therapy for penetrating ASCI may impair recovery of neurologic function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932887     DOI: 10.1097/00005373-199410000-00009

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  9 in total

1.  Role of glucocorticosteroids in treatment of acute spinal cord injury.

Authors:  E Savitsky
Journal:  West J Med       Date:  1996-01

Review 2.  Chemical priming for spinal cord injury: a review of the literature part II-potential therapeutics.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-21       Impact factor: 1.475

Review 3.  Chemical priming for spinal cord injury: a review of the literature. Part I-factors involved.

Authors:  Martin M Mortazavi; Ketan Verma; Aman Deep; Fatemeh B Esfahani; Patrick R Pritchard; R Shane Tubbs; Nicholas Theodore
Journal:  Childs Nerv Syst       Date:  2010-12-18       Impact factor: 1.475

Review 4.  A review: the role of high dose methylprednisolone in spinal cord trauma in children.

Authors:  Janine N Pettiford; Jai Bikhchandani; Daniel J Ostlie; Shawn D St Peter; Ronald J Sharp; David Juang
Journal:  Pediatr Surg Int       Date:  2011-10-13       Impact factor: 1.827

Review 5.  CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure.

Authors:  Michael T Fitch; Jerry Silver
Journal:  Exp Neurol       Date:  2007-05-31       Impact factor: 5.330

6.  Penetrating spine injury bisecting thoracic spinal canal with no significant neurological deficits-The midline cord syndrome.

Authors:  Bhaskar Sarkar; Kaustubh Ahuja; Arghya Kundu Choudhury; Rohit Jain
Journal:  Spinal Cord Ser Cases       Date:  2018-11-13

7.  Penetrating thoracic spinal cord injury with ice pick extending into the aorta. A technical note and review of the literature.

Authors:  Rani Nasser; Jonathan Nakhla; Saadat Sharif; Merritt Kinon; Reza Yassari
Journal:  Surg Neurol Int       Date:  2016-11-09

8.  A Bibliometric Analysis of Publications on Spinal Cord Injury Treatment With Glucocorticoids Using VOSviewer.

Authors:  Yu Zhang; An-An Li; Shi-Ning Xiao; Nan-Shan Zhong; Wei-Lai Tong; Shi-Jiang Wang; Jia-Ming Liu; Zhi-Li Liu
Journal:  Front Public Health       Date:  2022-08-08

Review 9.  Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Systematic Review and Meta-Analysis.

Authors:  Nathan Evaniew; Emilie P Belley-Côté; Nader Fallah; Vanessa K Noonan; Carly S Rivers; Marcel F Dvorak
Journal:  J Neurotrauma       Date:  2015-12-15       Impact factor: 5.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.